Silver Spring, MD—On June 30, 2022, the Food and Drug Administration (FDA) issued warning letters, jointly with the Federal Trade Commission (FTC), to four companies selling kratom products. FDA stated that it has not approved kratom for the treatment or cure of opioid use disorder and withdrawal symptoms.
FDA also noted that it has received “concerning reports about the safety of kratom.” The agency is “actively evaluating all available scientific information on this issue and advises consumers not to use kratom or essential oils for the treatment or cure of opioid use disorder and withdrawal symptoms.”
The 4 kratom companies receiving letters:
- Herbsens Botanicals
- Klarity Kratom
- Kratom Exchange
- Omni Consumer Products LLC d/b/a YoKratom
Read more at Whole Foods Magazine